Many PARP inhibitors have been developed and approved by the FDA for treating patients with recurrent Platinum-sensitive ovarian cancer, with or without the loss of the BRCA1/2 gene [15,55,56,57]. This evidence concerns the gene BRCA1 and ovarian carcinoma.